🇨🇳 China's NMPA just approved Hengrui's Herombopag for 2 new indications — CTIT (adult solid tumor patients) and pediatric chronic ITP.
This makes it the world's FIRST TPO-RA approved for CTIT 🏆
5 indications total now approved in China.
@dengyuemedicine.bsky.social